Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Invested Capital (2017 - 2025)

Puma Biotechnology's Invested Capital history spans 9 years, with the latest figure at $152.9 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 11.21% year-over-year to $152.9 million; the TTM value through Dec 2025 reached $152.9 million, up 11.21%, while the annual FY2025 figure was $152.9 million, 11.21% up from the prior year.
  • Invested Capital reached $152.9 million in Q4 2025 per PBYI's latest filing, up from $149.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $152.9 million in Q4 2025 to a low of -$10.9 million in Q3 2021.
  • Average Invested Capital over 5 years is $70.0 million, with a median of $61.2 million recorded in 2021.
  • Peak YoY movement for Invested Capital: plummeted 307.6% in 2021, then surged 983.4% in 2022.
  • A 5-year view of Invested Capital shows it stood at -$2.4 million in 2021, then soared by 983.4% to $21.6 million in 2022, then surged by 304.66% to $87.4 million in 2023, then surged by 57.2% to $137.5 million in 2024, then rose by 11.21% to $152.9 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Invested Capital are $152.9 million (Q4 2025), $149.0 million (Q3 2025), and $138.7 million (Q2 2025).